Amarin is a biopharmaceutical company focusing on cardiovascular disease. The company’s lead product is a prescription grade omega-3 fatty acid that is marketed in the US for hypertriglyceridaemia. It has also shown positive results in Phase III trials for mixed dyslipidaemia.

LocationDublin, Ireland
CEOJohn Thero
Websitewww.amarincorp.com